Variable Effects of Growth Factors on Developmental Gene Expression in Pancreatic Cancer Cells

Gnatenko, D. A.; Kopantzev, E. P.

doi:10.1134/s1607672918040105

Cited by 3 publications

(7 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…118 Hence, it is required to reduce adverse effects of FGFR inhibitors. Overexpression; associates with advanced tumour stage and shorter survival 40,41,43,44,61 FGF-2 Induction of phosphorylation of E-cadherin and β-catenin, regulation of SOX-9, HNF3β, HES1, ornithine decarboxylase…”

Section: Fg Fr Inhib Itor S For Pan Cre Ati C C An Cer Tre Atmentmentioning

confidence: 99%

“…Overexpression; associates with advanced tumour stage and shorter survival; promotes cell growth and invasion 40,41,43,44,47,49,61 FGF-5 Induction of MAPK activity Overexpression; promotes the cell growth 55…”

Section: Con Clus I On and Per S Pec Tivementioning

confidence: 99%

“…Overexpression; promotes migration and invasion 59,61 FGF-10 Increases MT1-MMP and TGF-β1, regulation of SOX-9, HNF3β, HES1…”

Section: Fgf-7mentioning

confidence: 99%

“…Induces cell migration and invasion. Overexpressed; a biomarker for chemotherapeutic treatment response [61][62][63]…”

Section: Fgf-7mentioning

confidence: 99%

See 3 more Smart Citations

Deciphering role of FGFR signalling pathway in pancreatic cancer

Kang

Zeng

et al. 2019

Cell Proliferation

View full text Add to dashboard Cite

Recently, fibroblast growth factors are identified to play a vital role in the development and progression of human pancreatic cancer. FGF pathway is critical involved in numerous cellular processes through regulation of its downstream targets, including proliferation, apoptosis, migration, invasion, angiogenesis and metastasis. In this review article, we describe recent advances of FGFR signalling pathway in pancreatic carcinogenesis and progression. Moreover, we highlight the available chemical inhibitors of FGFR pathway for potential treatment of pancreatic cancer. Furthermore, we discuss whether targeting FGFR pathway is a novel therapeutic strategy for pancreatic cancer clinical management.

show abstract

Section: Fg Fr Inhib Itor S For Pan Cre Ati C C An Cer Tre Atmentmentioning

confidence: 99%

Section: Con Clus I On and Per S Pec Tivementioning

confidence: 99%

See 2 more Smart Citations

Deciphering role of FGFR signalling pathway in pancreatic cancer

Kang

Zeng

et al. 2019

Cell Proliferation

View full text Add to dashboard Cite

show abstract

“…Furthermore, P16 deletion is significantly associated with shorter average survival times and acts as a predictive marker for poor prognosis in patients with pancreatic ductal adenocarcinoma ( Luo et al 2013 ). In addition, many studies suggest that the abnormal expression of growth factors or their receptors may affect cellular functions and the tumorigenicity of pancreatic cancer ( Ebert et al 1995 ; Gnatenko et al 2018 ). It has been reported that high plasma levels of the transforming growth factor (TGF)- β1 in pancreatic cancer patients is associated with advanced stages of the disease and significantly shorter survival times ( Javle et al 2014 ).…”

Section: Introductionmentioning

confidence: 99%

Screening and discrimination of optimal prognostic genes for pancreatic cancer based on a prognostic prediction model

Chen¹,

Song²,

Zeng³

et al. 2021

G3 Genes|Genomes|Genetics

View full text Add to dashboard Cite

The prognosis of pancreatic cancer is poor because patients are usually asymptomatic in the early stage and the early diagnostic rate is low. Therefore, in this study, we aimed to identify potential prognosis-related genes in pancreatic cancer to improve diagnosis and the outcome of patients. The mRNA expression profile data from The Cancer Genome Atlas database and GSE79668, GSE62452, and GSE28735 datasets from Gene Expression Omnibus were downloaded. The prognosis-relevant genes and clinical factors were analyzed using Cox regression analysis and the optimal gene sets were screened using the Cox proportional model. Next, the Kaplan-Meier survival analysis was used to evaluate the relationship between risk grouping and patient prognosis. Finally, an optimal gene-based prognosis prediction model was constructed and validated using a test dataset to discriminate the model accuracy and reliability. The results showed that 325 expression variable genes were identified, and 48 prognosis-relevant genes and three clinical factors, including lymph node stage (pathologic N), new tumor, and targeted molecular therapy were preliminarily obtained. In addition, a gene set containing 16 optimal genes was identified and included FABP6, MAL, KIF19, and REG4, which were significantly associated with the prognosis of pancreatic cancer. Moreover, a prognosis prediction model was constructed and validated to be relatively accurate and reliable. In conclusion, a gene set consisting of 16 prognosis-related genes was identified and a prognosis prediction model was constructed, which is expected to be applicable in the clinical diagnosis and treatment guidance of pancreatic cancer in the future.

show abstract

Dissecting FGF Signalling to Target Cellular Crosstalk in Pancreatic Cancer

Carter

Coetzee

Bort

et al. 2021

Cells

View full text Add to dashboard Cite

Pancreatic ductal adenocarcinoma (PDAC) has a poor prognosis with a 5 year survival rate of less than 8%, and is predicted to become the second leading cause of cancer-related death by 2030. Alongside late detection, which impacts upon surgical treatment, PDAC tumours are challenging to treat due to their desmoplastic stroma and hypovascular nature, which limits the effectiveness of chemotherapy and radiotherapy. Pancreatic stellate cells (PSCs), which form a key part of this stroma, become activated in response to tumour development, entering into cross-talk with cancer cells to induce tumour cell proliferation and invasion, leading to metastatic spread. We and others have shown that Fibroblast Growth Factor Receptor (FGFR) signalling can play a critical role in the interactions between PDAC cells and the tumour microenvironment, but it is clear that the FGFR signalling pathway is not acting in isolation. Here we describe our current understanding of the mechanisms by which FGFR signalling contributes to PDAC progression, focusing on its interaction with other pathways in signalling networks and discussing the therapeutic approaches that are being developed to try and improve prognosis for this terrible disease.

show abstract

Variable Effects of Growth Factors on Developmental Gene Expression in Pancreatic Cancer Cells

Cited by 3 publications

References 6 publications

Deciphering role of FGFR signalling pathway in pancreatic cancer

Deciphering role of FGFR signalling pathway in pancreatic cancer

Screening and discrimination of optimal prognostic genes for pancreatic cancer based on a prognostic prediction model

Dissecting FGF Signalling to Target Cellular Crosstalk in Pancreatic Cancer

Contact Info

Product

Resources

About